Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanomaAndrew Haydon,Reinhard Dummer,Keith Flaherty,Caroline Robert,Ana M. Arance,Jan Willem de Groot,Clause Garbe,Helen Gogas,Ralf Gutzmer,Ivana Krajsova,Gabriella Liszkay,Carmen Loquai,Mario Mandala,Dirk Schadendorf,Naoya Yamazaki,Fabien Zohren,Victoria Atkinson,Michael Millward,Andrew Hill,Michelle L. Edwards,Paolo A. AsciertoJOURNAL OF CLINICAL ONCOLOGY（2021）引用 32|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
